We have demonstrated neuro-protection of G-CSF gene therapy in the BCAO mouse stroke model as shown by a decrease of DRP1, a marker of mitochondrial stress in frontal and middle brain in the G-CSF treated group. This evidence concerns the gene CSF3 and Stroke.